STOCK TITAN

Organogenesis Holdings Inc - ORGO STOCK NEWS

Welcome to our dedicated news page for Organogenesis Holdings (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organogenesis Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organogenesis Holdings's position in the market.

Rhea-AI Summary
Organogenesis Holdings Inc. (ORGO) will report its first-quarter fiscal year 2024 financial results on May 9, 2024. The company focuses on regenerative medicine products for Advanced Wound Care and Surgical & Sports Medicine markets. A conference call will be held to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.62%
Tags
conferences earnings
-
Rhea-AI Summary
Organogenesis Holdings Inc. reported financial results for Q4 2023 and FY 2023, with a decrease in net revenue compared to the previous year. Despite challenges, the company aims for revenue growth in 2024 through commercial support programs and new product launches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.21%
Tags
-
Rhea-AI Summary
Organogenesis Holdings Inc. (ORGO) to participate in the BTIG Snowbird MedTech Conference without a formal presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
conferences
Rhea-AI Summary
Organogenesis Holdings Inc. (ORGO) will report its Q4 and fiscal year 2023 financial results on February 29th, followed by a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
conferences earnings
-
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported a decrease in net revenue for the third quarter of 2023, driven by a decrease in net revenue for Advanced Wound Care and Surgical & Sports Medicine products. Despite this, the company saw an increase in net income and adjusted EBITDA compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.17%
Tags
-
Rhea-AI Summary
Organogenesis Holdings Inc. to report Q3 2023 financial results on November 9th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
Rhea-AI Summary
Organogenesis Holdings Inc. applauds the decision by MACs to withdraw LCDs for Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers, which would have taken effect on October 1. This decision will positively impact the lives of thousands of patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.92%
Tags
none
-
Rhea-AI Summary
Organogenesis Holdings Inc. to participate in Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
conferences
-
Rhea-AI Summary
Organogenesis Holdings Inc. reports financial results for Q2 2023, with net revenue of $117.3 million, a decrease of $4.1 million compared to Q2 2022. Net income for Q2 2023 was $5.3 million, compared to $8.7 million in Q2 2022. Adjusted EBITDA was $15.4 million, a decrease of $3.2 million. The company is withdrawing its fiscal year 2023 guidance due to uncertainty resulting from recently published local coverage determinations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.88%
Tags
Rhea-AI Summary
Organogenesis Holdings Inc. will report its Q2 2023 financial results on August 9th and host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
conferences earnings
Organogenesis Holdings Inc

Nasdaq:ORGO

ORGO Rankings

ORGO Stock Data

380.05M
61.84M
33.32%
44.97%
5.48%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Canton

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.